International Psoriasis Council

Advancing Knowledge. Improving Care.

Introducing our Latest IPC Councilors: Experts in Psoriasis Treatment and Research

Join us in welcoming IPC’s newest Councilors, Marwa Amer, Paola Di Meglio, Albert Duvetorp, Melinda Gooderham, Chih-Hung Lee, Xiao-Yong Man, and Juul van den Reek. This group of experts was recently appointed and selected by the IPC Board of Directors for their dedication to enhancing global research on psoriasis and improving patient care.

As IPC Councilors, they will use their invaluable expertise to better IPC initiatives and help advance psoriasis research, treatment, and education on a global scale. We encourage you to learn more about this group of psoriasis experts through their comprehensive biographies.

Let’s extend a warm welcome to Marwa Amer, Paola Di Meglio, Albert Duvetorp, Melinda Gooderham, Chih-Hung Lee, Xiao-Yong Man, and Juul van den Reek as members of the IPC Councilor community, underscoring IPC’s commitment to driving positive change and improvement in global psoriasis care.

Marwa Amer, MD, PhD

Kasr Al-Ainy Hospital, Cairo University

Cairo, Egypt

IPC Councilor

Bio

Paola Di Meglio, PhD

King’s College London

London, United Kingdom

IPC Councilor

Bio

Albert Duvetorp, MD, PhD

Skåne University Hospital

Malmö, Sweden

IPC Councilor

Bio

Melinda Gooderham, MSc, MD, FRCPC

SKiN Centre for Dermatology

Peterborough, Ontario, Canada

IPC Councilor

Bio

Chih-Hung Lee , MD, PhD

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung, Taiwan

IPC Councilor

Bio

Xiao-Yong Man, MD, PhD

The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, China

IPC Councilor

Bio

Juul van den Reek, MD, PhD

Radboud University Medical Center

Nijmegen, Netherlands

IPC Councilor

Bio

Categories

Recent Posts

Approaching Challenging Patient Interactions with Empathy

Next Generation of Leaders: 2025 IPC Fellows Transition to Jr. Councilors

Highlights from the 2026 American Academy of Dermatology (AAD) Annual Meeting: Diagnostic Complexity, Therapeutic Advances, and Emerging Research

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026